This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 23 Oct 2023

Praluent® (alirocumab) Administration

Author: Sanofi

Editorial Team

  
Praluent logo

Prescribing Information(GB)

Prescribing Information(NI)

Praluent® can be injected subcutaneously into the thigh, abdomen or upper arm. Patients should rotate the injection site with each injection.1

Ease of use assessed as ≥9.8 out of 10 in all assessments for both devices*2

300 mg Q4W

75 mg and 150 mg Q2W

*Study of 69 patients who randomly received unsupervised, self-administered alirocumab 300 mg via 1 x 300 mg injection with the SYDNEY device (n=35) or 2 x 150 mg injections with the currently approved auto-injector (n=34). Possible answers ranged from 1 (very dissatisfied) to 10 (very satisfied).
**Evaluated in a cross-sectional, non-interventional study involving 151 patients enrolled in Praluent® phase 3 trials.
SmPC=summary of product characteristics.

Up to 30 days out of the fridge1

  • Store in a refrigerator (2°C to 8°C). Do not freeze
  • PRALUENT® can be kept outside a refrigerator below 25°C and protected from light for a single period not exceeding 30 days
  • After removal from the refrigerator, the medicinal product must be used within 30 days or discarded.

Although many patients requiring lipid lowering therapies are not experienced with self-injected medication, in a real world study, results indicated that the pre-filled pen was well-accepted by patients.6

Dosage information

The usual starting dose for PRALUENT® is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously. The dose of PRALUENT® can be individualised based on patient characteristics such as baseline LDL-C level, goal of therapy, and response. Lipid levels can be assessed 4 to 8 weeks after treatment initiation or titration, and dose adjusted accordingly (up-titration or down-titration). If additional LDL-C reduction is needed in patients treated with 75 mg once every 2 weeks or 300 mg once every 4 weeks (monthly), the dosage may be adjusted to the maximum dosage of 150 mg once every 2 weeks. If a dose is missed, the patient should administer the injection as soon as possible and thereafter resume treatment on the original schedule.

SEE MORE FROM SCIENCE

Praluent®

Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

Patient Website

Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Get in touch with the Dyslipidaemia Team
MAT-XU-2201545 (v5.0) Date of Preparation: October 2023
References
  1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed March 2023.
  2. Frias JP, Koren MJ, Loizeau V, et al. The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device. Clinical Therapeutics. 2020; 42(1):94-107.
  3. Praluent Patient information lealfet 150mg. March 2023.
  4. Praluent Patient information leaflet 300mg. March 2023.
  5. Tatlock S, et al. Value Health 2017;20:430–440.
  6. Roth E, et al. Clin Ther 2015;37(9):1945–1954.

MAT-XU-2204608 (v3.0) Date of Preparation: October 2023